Ipatasertib, a potent AKT inhibitor, was combined with rucaparib in a phase Ib trial (NCT03840200) in breast, ovarian, and prostate cancer, based on preclinical data suggesting that synergistic effects may overcome PARPi resistance [81,82]. Here, AKT1 is linked to prostate carcinoma.